A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis

Hyung Soon Park, Sun Young Rha, Hyo Song Kim, Woo Jin Hyung, Ji Soo Park, Hyun Cheol Chung, Sung Hoon Noh, Hei Cheul Jeung

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.

Original languageEnglish
Pages (from-to)142-150
Number of pages9
JournalOncology
Volume80
Issue number1-2
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

Stomach Neoplasms
Neoplasm Metastasis
Bone and Bones
Drug Therapy
Survival
Carcinoembryonic Antigen
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Hyung Soon ; Rha, Sun Young ; Kim, Hyo Song ; Hyung, Woo Jin ; Park, Ji Soo ; Chung, Hyun Cheol ; Noh, Sung Hoon ; Jeung, Hei Cheul. / A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. In: Oncology. 2011 ; Vol. 80, No. 1-2. pp. 142-150.
@article{7462829b68b14f2f81ee36bd10bdc012,
title = "A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis",
abstract = "Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4{\%}) of 8,633 patients: 126 patients (62{\%}) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59{\%}) received systemic chemotherapy. The median survival time was 103 days (95{\%} CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.",
author = "Park, {Hyung Soon} and Rha, {Sun Young} and Kim, {Hyo Song} and Hyung, {Woo Jin} and Park, {Ji Soo} and Chung, {Hyun Cheol} and Noh, {Sung Hoon} and Jeung, {Hei Cheul}",
year = "2011",
month = "6",
day = "1",
doi = "10.1159/000328507",
language = "English",
volume = "80",
pages = "142--150",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1-2",

}

A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. / Park, Hyung Soon; Rha, Sun Young; Kim, Hyo Song; Hyung, Woo Jin; Park, Ji Soo; Chung, Hyun Cheol; Noh, Sung Hoon; Jeung, Hei Cheul.

In: Oncology, Vol. 80, No. 1-2, 01.06.2011, p. 142-150.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis

AU - Park, Hyung Soon

AU - Rha, Sun Young

AU - Kim, Hyo Song

AU - Hyung, Woo Jin

AU - Park, Ji Soo

AU - Chung, Hyun Cheol

AU - Noh, Sung Hoon

AU - Jeung, Hei Cheul

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.

AB - Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.

UR - http://www.scopus.com/inward/record.url?scp=79958770676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958770676&partnerID=8YFLogxK

U2 - 10.1159/000328507

DO - 10.1159/000328507

M3 - Review article

C2 - 21677462

AN - SCOPUS:79958770676

VL - 80

SP - 142

EP - 150

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1-2

ER -